Drug/Small Molecule:
metaraminol

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug/small molecule. To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Hydroxynorephedrine
  • L-Metaraminol
  • M-Hydroxy Norephedrine
  • M-Hydroxyphenylpropanolamine
  • M-Hydroxypropadrine
  • Metaraminol Bitartrate
  • Metaraminolum [INN-Latin]
  • Metaraminolum [Latin]
Trade Names
  • Aramine
  • Icoral B
  • Metaradrine
  • Pressonex
  • Pressorol
Brand Mixture Names

PharmGKB Accession Id:
PA164748761

Description

An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine. It has been used primarily as a vasoconstrictor in the treatment of hypotension.

Source: Drug Bank

Indication

For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Metaraminol acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic & diastolic). Its effect is thought to be associated with the inhibition of adenyl cyclase which leads to an inhibition of the production of cAMP. Another effect of Metaraminol is that it releases norepinephrine from its storage sites indirectly.

Source: Drug Bank

Pharmacology

Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol acts on both alpha1-adrenergic receptors but appears to have no effect on beta-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

Approximately 45%

Source: Drug Bank

Absorption

The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection.

Source: Drug Bank

Toxicity

LD 50=240 mg/kg (rat, oral); LD 50=99 mg/kg (mouse, oral)

Source: Drug Bank

Chemical Properties

Chemical Formula

C9H13NO2

Source: Drug Bank

Isomeric SMILES

C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N

Source: Drug Bank

C[C@H](N)[C@H](O)C1=CC(O)=CC=C1

Source: Drug Bank

Canonical SMILES

C[C@H](N)[C@H]

Source: Drug Bank

Average Molecular Weight

167.205

Source: Drug Bank

Monoisotopic Molecular Weight

167.094628665

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Drug Targets

Gene Description
ADRA1A (source: Drug Bank)

Drug Interactions

Drug Description
metaraminol The tricyclic increases the sympathomimetic effect (source: Drug Bank)
metaraminol The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of metaraminol. (source: Drug Bank)
metaraminol The tricyclic increases the sympathomimetic effect (source: Drug Bank)
metaraminol The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of metaraminol. (source: Drug Bank)
metaraminol The tricyclic increases the sympathomimetic effect (source: Drug Bank)
metaraminol The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of metaraminol. (source: Drug Bank)
metaraminol The tricyclic increases the sympathomimetic effect (source: Drug Bank)
metaraminol The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of metaraminol. (source: Drug Bank)
metaraminol The tricyclic increases the sympathomimetic effect (source: Drug Bank)
metaraminol The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of metaraminol. (source: Drug Bank)
metaraminol Metaraminol may decrease the effect of guanethidine. (source: Drug Bank)
metaraminol The tricyclic increases the sympathomimetic effect (source: Drug Bank)
metaraminol The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of metaraminol. (source: Drug Bank)
metaraminol Increased arterial pressure (source: Drug Bank)
metaraminol Increased arterial pressure (source: Drug Bank)
metaraminol Possible increase of arterial pressure (source: Drug Bank)
metaraminol Increased arterial pressure (source: Drug Bank)
metaraminol Moclobemide increases the sympathomimetic effect of metaraminol. (source: Drug Bank)
metaraminol The tricyclic increases the sympathomimetic effect (source: Drug Bank)
metaraminol The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of metaraminol. (source: Drug Bank)
metaraminol Increased arterial pressure (source: Drug Bank)
metaraminol Increased arterial pressure (source: Drug Bank)
metaraminol Increased arterial pressure (source: Drug Bank)

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00610
ChEBI:
6794
KEGG Compound:
C07146
PubChem Compound:
5906
PubChem Substance:
46505593
9355
ChemSpider:
5695
Therapeutic Targets Database:
DAP000225

Clinical Trials

These are trials that mention metaraminol and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.